Objective: To determine the incidence of premature luteinization in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian hyperstimulation (COH) with exogenous gonadotropin/GnRH antagonist (GnRH-a); to compare clinical outcomes in patients with and without premature luteinization.

Design: Retrospective case series.

Setting: IVF clinic.

Patient(s): Thirty-five treatment cycles in 30 patients with PCOS.

Intervention(s): Controlled ovarian hyperstimulation with gonadotropin/GnRH-a protocol.

Main Outcome Measure(s): Premature luteinization defined as a P concentration of >/=1.3 ng/mL on the day of hCG administration; number of oocytes and two pronuclei (2PN) embryos; implantation and clinical pregnancy rates (PR).

Result(s): The incidence of premature luteinization was 28%. Compared with those without premature luteinization, patients with premature luteinization had a higher number of oocytes retrieved (24.1 +/- 13.3 vs. 12.0 +/- 5.9) and greater number of mature oocytes (19.7 +/- 11.7 vs. 9.5 +/- 4.5), respectively. The number of good quality embryos and embryos transferred was not significantly different between groups. Although implantation rates (56% vs. 40%) and clinical PRs (36% vs. 30%) were higher in patients without premature luteinization, the differences were not statistically significant.

Conclusion(s): The patients with PCOS with premature luteinization had a higher number of oocytes retrieved and mature oocytes, and similar clinical PRs as patients with PCOS without premature luteinization.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fertnstert.2008.02.009DOI Listing

Publication Analysis

Top Keywords

premature luteinization
36
patients premature
12
number oocytes
12
premature
10
polycystic ovary
8
ovary syndrome
8
incidence premature
8
luteinization
8
luteinization patients
8
controlled ovarian
8

Similar Publications

Aim: This study aims to assess the impacts of various trigger day progesterone (P) and luteinizing hormone (LH) levels on live birth rates (LBRs) in fresh in vitro fertilization (IVF) cycles, considering their elevation from stimulation and premature luteinization.

Methods: This retrospective cohort study included the first ovarian stimulation cycles with GnRH antagonist protocol of 1253 patients who underwent intracytoplasmic sperm injection and fresh embryo transfer at a tertiary clinic's IVF center between 2010 and 2016. Participants were divided into four groups based on trigger day serum P and LH levels, using the 90th percentile thresholds for P (1.

View Article and Find Full Text PDF

The objective of this study was to examine the efficacy of the concurrent utilization of estradiol valerate and kuntai capsule (a Chinese herbal preparation) in addressing premature ovarian failure (POF) and its ramifications for ovarian hemodynamics and sex hormone levels. A retrospective study of 104 patients with POF was conducted, dividing them into control (n=50) and observation groups (n=54). The control group received estradiol valerate, while the observation group received estradiol valerate and KunTai capsules over 12 weeks.

View Article and Find Full Text PDF

Study Question: Are live birth rates (LBRs) per woman following flexible progestin-primed ovarian stimulation (fPPOS) treatment non-inferior to LBRs per woman following the conventional GnRH-antagonist protocol in expected suboptimal responders undergoing freeze-all cycles in assisted reproduction treatment?

Summary Answer: In women expected to have a suboptimal response, the 12-month likelihood of live birth with the fPPOS treatment did not achieve the non-inferiority criteria when compared to the standard GnRH antagonist protocol for IVF/ICSI treatment with a freeze-all strategy.

What Is Known Already: The standard PPOS protocol is effective for ovarian stimulation, where medroxyprogesterone acetate (MPA) is conventionally administered in the early follicular phase for ovulatory suppression. Recent retrospective cohort studies on donor cycles have shown the potential to prevent premature ovulation and maintain oocyte yields by delaying the administration of MPA until the midcycle (referred to as fPPOS), similar to GnRH antagonist injections.

View Article and Find Full Text PDF

Objectives: To establish an efficient and clinically applicable predictive model and scoring system for central precocious puberty (CPP) in girls, and to develop a diagnostic prediction application.

Methods: A total of 342 girls aged 4 to 9 years with precocious puberty were included, comprising 216 cases of CPP and 126 cases of isolated premature thelarche. Lasso regression was used to screen for predictive factors, and logistic regression was employed to establish the predictive model.

View Article and Find Full Text PDF

IL-33 and soluble ST2 in follicular fluid are associated with premature ovarian insufficiency.

Front Endocrinol (Lausanne)

December 2024

Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Background: Premature ovarian insufficiency (POI) is a common reproductive disease that is associated with chronic inflammation in ovaries. Interleukin 33 (IL-33) is a pro-inflammatory IL-1 family cytokine, and functions as an alarmin reflecting inflammatory reaction. Our study aimed to investigate levels of IL-33 and its soluble receptor (sST2) in both follicular fluid (FF) and paired serum during different stages of POI, and evaluate their predictive potentials for POI.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!